Steven Stoner, PharmD, a board-certified psychiatric pharmacist and associate dean for student affairs at the University of Missouri–Kansas City, School of Pharmacy, recently discussed the potential for dextromethorphan/bupropion (DM/BUP) to expand its role in psychiatric care beyond its current approvals for major depressive disorder and agitation associated with Alzheimer’s disease.1 This exploration is fueled by the drug’s unique mechanism of action and a favorable safety profile, particularly in vulnerable patient populations.
Beyond traditional Approaches: The Limitations of Monoamine-Based Therapies
For decades, the cornerstone of psychiatric treatment has revolved around modulating monoamine neurotransmitters – serotonin, norepinephrine, and dopamine.While effective for many, these “monoaminergic” approaches often fall short for individuals with treatment-resistant conditions or those experiencing specific symptom clusters. Many patients continue to struggle with persistent symptoms despite trying multiple medications that target these pathways. This highlights a critical need for novel therapeutic strategies.
Dr. Stoner points out that the history of psychopharmacology is replete with examples of drugs initially approved for one condition finding valuable applications in others. Antidepressants are frequently used off-label for anxiety disorders, and second-generation antipsychotics have become common augmentation agents in mood disorders. This repurposing of medications underscores the complex interplay of neurobiological systems and the potential for drugs to exert effects beyond their primary targets.
DM/BUP: A Novel Mechanism of action
Dextromethorphan/bupropion distinguishes itself from traditional antidepressants and antipsychotics through its unique mechanism of action. It targets the N-methyl-D-aspartate (NMDA) receptor and the sigma-1 receptor. The NMDA receptor plays a crucial role in synaptic plasticity, learning, and memory, and its dysregulation has been implicated in several psychiatric disorders, including depression, schizophrenia, and post-traumatic stress disorder (PTSD). The sigma-1 receptor is involved in neuroprotection and the modulation of neurotransmitter release.
bupropion, a well-known antidepressant, is included in the combination to boost levels of dextromethorphan, enhancing its therapeutic effect. This synergistic action is believed to contribute to DM/BUP’s efficacy in treatment-resistant depression, where conventional monoaminergic agents have failed.Research suggests that NMDA receptor modulation may offer a different pathway to alleviate depressive symptoms, particularly those characterized by cognitive impairment and emotional blunting.
The Potential for expanded Applications
Given its novel mechanism, DM/BUP is being considered for a range of other psychiatric conditions. Potential areas of exploration include:
- Treatment-resistant Depression: As demonstrated in clinical trials, DM/BUP offers a viable option for patients who haven’t responded to traditional antidepressants.
- Anxiety Disorders: The sigma-1 receptor modulation may have anxiolytic effects, possibly benefiting individuals with generalized anxiety disorder, social anxiety, or panic disorder.
- Post-Traumatic Stress Disorder (PTSD): NMDA receptor dysregulation is implicated in the development and maintenance of PTSD.DM/BUP’s modulation of this receptor could potentially alleviate symptoms like intrusive memories and hyperarousal.
- Schizophrenia: Early research suggests that NMDA receptor hypofunction may contribute to the negative symptoms of schizophrenia (e.g., flat affect, social withdrawal). DM/BUP could potentially address these debilitating symptoms.
- Cognitive Impairment: The NMDA receptor’s role in learning and memory suggests DM/BUP could be beneficial in conditions involving cognitive decline, such as mild cognitive impairment.
A Favorable Safety Profile: A Key Advantage
A critically important advantage of DM/BUP is its comparatively favorable safety profile. Many existing psychiatric medications are associated with significant side effects. antipsychotics, for example, carry risks of metabolic syndrome (weight gain, diabetes, high cholesterol) and movement disorders. Benzodiazepines,commonly used for anxiety,can cause sedation,cognitive impairment,and dependence.
Dr. Stoner emphasizes that DM/BUP avoids these common and severe side effects.While not entirely without risks – potential drug interactions and mild side effects like nausea are possible – its tolerability profile makes it an attractive option, especially for elderly patients or those with co-existing medical conditions. Axsome therapeutics, the manufacturer of auvelity (the brand name for DM/BUP), highlights the drug’s lack of common antidepressant side effects like sexual dysfunction, weight gain, and sleep disturbances.
The future of DM/BUP in Psychiatry
The potential of DM/BUP extends beyond its current indications. If ongoing research continues to demonstrate clinical benefit in other psychiatric disorders, its unique safety and tolerability profile will likely drive its wider adoption. The key will be conducting rigorous clinical trials to establish efficacy and identify the patient populations most likely to benefit from this novel approach.
As Dr. Stoner asserts, a favorable risk-benefit profile is paramount when considering new treatments, particularly in psychiatry where patients frequently enough require long-term medication management. DM/BUP represents a promising step towards more targeted and well-tolerated therapies for a range of challenging mental health conditions.
